News and Announcements
CAVATAK Immunotherapy Combo shows more Anti-cancer Activity
- Published October 01, 2014 1:49PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
ASX and Media Release, 30 September 2014
CAVATAK Immunotherapy Combination Demonstrates Superior Anti-cancer Activity Presented at the European society for medical oncology (ESMO) 2014 Congress
•Preclinical studies show CAVATAK combined with checkpoint inhibitor agents provides significantly greater anti-tumour activity than checkpoint inhibitors alone
•Data suggest an anti-tumour immune response
•Results strengthen CAVATAK ‘s potential role as combination therapy with checkpoint inhibitors, a major new class of anticancer immunotherapies
30 September 2014, Sydney, Australia: Viralytics Limited (ASX:VLA, OTC:VRACY) overnight announced at the European Society for Medical Oncology (ESMO) 2014 Congress in Madrid that preclinical studies have generated further evidence of improved CAVATAK anti-cancer activity when used in combination with immune checkpoint inhibitors, a new class of cancer immunotherapies with blockbuster potential. CAVATAK is a proprietary formulation of a common cold virus that hass been shown to preferentially infect and attack cancer cells.
To view the full ASX and Media Release please click here.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
